Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.
Study Overview
Status
Detailed Description
There is substantial data to suggest that EGFR and Her-2/neu expressions are important predictors for prognosis in HNSCC. EGFR blockade with a monoclonal antibody in conjunction with radiotherapy has been shown to improve survival over radiotherapy alone in patients with locally advanced HNSCC. Dual inhibition of EGFR and ErbB2 tyrosine kinases results in greater inhibitory effect of the downstream signaling pathways in cancer cells than inhibition of either receptor alone. Phase I studies in HNSCC suggested that the drug is well tolerated when delivered either alone or concurrently with cisplatin based chemoradiotherapy in HNSCC.
We propose to combine lapatinib with RT alone in patients with locally advanced HNSCC who cannot tolerate chemotherapy. The main objective of the study is to determine the efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression (TTP) in this group of patients. In addition, we will determine the 2-year locoregional control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these patients. We will also evaluate the profile and frequency of late toxicity, specifically mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with locally advanced HNSCC.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainsville, Florida, United States, 32610
- University of Florida Shands Cancer Center
-
-
New York
-
New York, New York, United States, 10003
- Beth Israel
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed stage III-IV HNSCC, pathologically confirmed (HNSCC from unknown primary sites are allowed)
- No evidence of distant metastasis
- No prior radiation therapy to the head and neck sites.
- Able to sign a study-specific informed consent form.
- Women of childbearing potential and men with partners capable of producing offspring must be willing to practice acceptable methods of birth control to prevent pregnancy.
- Left ventricular ejection fraction (LVEF) within the institutional normal range as measured by ECHO (If ECHO cannot be performed or if the Investigator feels that it is not conclusive to evaluate LVEF, then a MUGA scan should be performed).
Having one of the following parameters that would preclude the use of concurrent CRT:
- ECOG PS > 2.
- Creatinine > 1.3 or calculate or measure creatinine clearance < 60 ml/min.
- AST or ALT > 1.5 times normal limit but < 3 times normal limit
- Total bilirubin > 1.5 mg/dL but < 3mg/dL
- History of hearing loss that would preclude cisplatin chemotherapy. These would include the existing need of a hearing aid or a >= 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test.
- Pre-existing peripheral neuropathy that would preclude cisplatin chemotherapy
- Refuse or cannot tolerate chemotherapy
- Age 18 years or older
Exclusion Criteria:
- Known hypersensitivity to lapatinib or any of the excipients of this product (quinazolines).
- Uncontrolled angina, arrhythmia or congestive heart failure at the time of HNSCC diagnosis and treatment.
- History of myocardial infarction < 6 months from study entry.
- Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
- Prior treatment with EGFR or Her2/Neu directed therapies.
- HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with Lapatinib.
- Absolute neutrophil count < 1500/uL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Radiotherapy and Lapatinib with DCE-MRI
DCE-MRI will precede radiotherpy before and after Lapatinib loading.
1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy.
Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
|
1500 mg po daily orally
Other Names:
Standard of Care
Other Names:
Standard of Care, used to deliver IMRT
Other Names:
A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression Free Survival
Time Frame: 2 year PFS: PFS at 2 yrs after study enrollment
|
To determine the efficacy of combining lapatinib and radiotherapy in terms of Progression-free survival (PFS) in patients with locally advanced HNSCC who cannot tolerate concurrent chemoradiotherapy. Progression-free survival is defined is the time from starting treatment to the time of first documented tumor progression or death due to any cause, which ever occurs first. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST V1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
2 year PFS: PFS at 2 yrs after study enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival.
Time Frame: Two years survival rate after study enrollment
|
Overall survival is the time from starting treatment until death due to any cause.
For subjects who do not die, time to death will be censored at the time of last contact.
|
Two years survival rate after study enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENT0020
- 97864 (OTHER: Stanford University Alternate IRB Approval Number)
- LAP #109855 (OTHER: GlaxoSmithKline)
- 8857 (OTHER: Stanford IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.